Your browser doesn't support javascript.
loading
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer.
Wainberg, Zev A; Hochster, Howard S; Kim, Edward J; George, Ben; Kaylan, Aparna; Chiorean, E Gabriela; Waterhouse, David M; Guiterrez, Martin; Parikh, Aparna; Jain, Rishi; Carrizosa, Daniel Ricardo; Soliman, Hatem H; Lila, Thomas; Reiss, David J; Pierce, Daniel W; Bhore, Rafia; Banerjee, Sibabrata; Lyons, Larry; Louis, Chrystal U; Ong, Teng Jin; O'Dwyer, Peter J.
Afiliación
  • Wainberg ZA; Department of Hematology/Oncology, Ronald Reagan UCLA Medical Center, Los Angeles, California. ZWainberg@mednet.ucla.edu.
  • Hochster HS; Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  • Kim EJ; Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California.
  • George B; Department of Medical Oncology, Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Kaylan A; Department of Medicine, Northwestern University, Chicago, Illinois.
  • Chiorean EG; Department of GI Oncology & Phase I Programs, University of Washington School of Medicine, Seattle, Washington.
  • Waterhouse DM; Department of Medical Oncology and Hematology, Oncology Hematology Care, Inc, Cincinnati, Ohio.
  • Guiterrez M; Department of Medical Oncology, John Theurer Cancer Center, Hackensack, New Jersey.
  • Parikh A; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Jain R; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Carrizosa DR; Department of Hematology/Oncology, Levine Cancer Institute, Charlotte, North Carolina.
  • Soliman HH; Department of Women's Oncology, University of South Florida, Moffitt Cancer Center, Tampa, Florida.
  • Lila T; Department of Translational Development & Diagnostics, Bristol Myers Squibb, San Francisco, California.
  • Reiss DJ; Department of Informatics & Predictive Sciences, Bristol Myers Squibb, Seattle, Washington.
  • Pierce DW; Department of Translational Development & Diagnostics, Bristol Myers Squibb, San Francisco, California.
  • Bhore R; Department of Medical Affairs Leadership, Bristol Myers Squibb, Princeton, New Jersey.
  • Banerjee S; Department of Medical Affairs Leadership, Bristol Myers Squibb, Princeton, New Jersey.
  • Lyons L; Department of Medical Affairs Leadership, Bristol Myers Squibb, Princeton, New Jersey.
  • Louis CU; Department of Medical Affairs Leadership, Bristol Myers Squibb, Princeton, New Jersey.
  • Ong TJ; Department of Medical Affairs Leadership, Bristol Myers Squibb, Princeton, New Jersey.
  • O'Dwyer PJ; Department of Medical Oncology, University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania.
Clin Cancer Res ; 26(18): 4814-4822, 2020 09 15.
Article en En | MEDLINE | ID: mdl-32554514
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Desoxicitidina / Albúminas / Nivolumab Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Desoxicitidina / Albúminas / Nivolumab Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article